16 Stories

New Filing by Rand Paul Raises Securities Experts' Eyebrows

Discloses wife's COVID-related stock buy 16 months late, prompting whispers of insider trading

(Newser) - Rand Paul's headline-making week isn't over yet. First the Republican senator from Kentucky was booted from YouTube for a week for spreading misinformation on face masks. Now Paul, one of the most vocal lawmakers to break with federal health officials on how to handle COVID, has made a...

Giuliani Updates the World on His COVID Treatment

Trump's personal lawyer says he's receiving a potent cocktail of experimental drugs

(Newser) - Rudy Giuliani called into his own radio show Tuesday and revealed how his COVID-19 treatment is going—pretty well, it turns out. Speaking from his hospital room at Georgetown University Hospital in Washington, DC, Giuliani said he's getting some of the same drugs that perked up President Trump: a...

Remdesivir Wins Approval as COVID-19 Treatment

Antiviral drug has been found to shorten recovery times

(Newser) - Remdesivir on Thursday became the first fully approved treatment for COVID-19 in the US. The Food and Drug Administration had issued an emergency use authorization for the antiviral drug in May. FDA Commissioner made the announcement , CNBC reports. Remdesivir shortened recovery time for hospitalized patients; President Trump is among the...

New COVID Trials Will Be 'a Little Different From Most'

'Human challenge' studies in the UK will involve deliberately injecting healthy subjects with virus

(Newser) - Clinical trials for a COVID-19 vaccine are currently in their final stages via a number of drug companies, but a new set soon to begin in the UK promises to be "a little different from most." CNN reports the British government has signed a contract for the first...

WHO: Remdesivir Doesn't Aid Survival

Clinical trial involved 11K hospitalized patients

(Newser) - A clinical trial by the World Health Organization has shown that the remdesivir has little material effect on patients' chances of surviving COVID-19. The WHO's report on its Solidarity trial, involving remdesivir and three other possible drug treatments, said none of them "substantially affected mortality" among patients or...

Drugmaker Pauses Trial of COVID Antibody Treatment

Eli Lilly says it's for safety reasons, without elaborating

(Newser) - Drugmaker Eli Lilly, working to come up with an antibody treatment for COVID-19, has paused its phase three clinical trials after an independent data safety monitoring board (DSMB) raised concerns. "Safety is of the utmost importance to Lilly," a company spokeswoman said in a statement Tuesday, reports CNBC...

Trump Received 2nd Dose of Remdesivir

He'll take it for 5 days

(Newser) - In a Saturday night update, White House physician Sean Conley said that President Trump had that day received his second dose of remdesivir "without complications" following his initial dose on Friday, reports the Hill . Conley added that Trump has no fever and remains "off supplemental oxygen with a...

One Star Hit by COVID Flew Under the Radar, Until Now

64-year-old star was hospitalized for week in April with the virus but has since recovered

(Newser) - For anyone keeping track of the celebrities and other well-known figures who've been stricken with the coronavirus, there's a new one for your list—and he managed to fly under the radar for months. A representative for Mel Gibson confirms the 64-year-old actor and director was hospitalized in...

US Scoops Up Almost Every Dose of Remdesivir

Trump administration strikes a deal with maker Gilead

(Newser) - Remdesivir is one of two drugs that has been shown to help coronavirus patients, and the US will basically own all of the upcoming doses of it. The Guardian reports that the Trump administration has purchased nearly all of the remdesivir that is available for the next three months. Specifically,...

Drugmaker Sets Price on COVID Drug
Drugmaker Sets Price
on COVID Drug

Drugmaker Sets Price on COVID Drug

Remdesivir will cost $3,120 per treatment course for typical US patient with insurance

(Newser) - Gilead Sciences is out with its much-anticipated price for a drug to treat COVID-19 patients: For a five-day treatment course of remdesivir, figure $3,120 for the typical US patient with commercial insurance, reports the Wall Street Journal . That would be the amount the drugmaker would charge the hospital, not...

Big Question on Hot COVID Drug: How Much Will It Cost?
$4,500 or $10? Manufacturer
of COVID Drug Has Big Decision
in case you missed it

$4,500 or $10? Manufacturer of COVID Drug Has Big Decision

All eyes on Gilead Sciences, manufacturer of remdesivir

(Newser) - Now that the FDA has approved the drug remdesivir for the treatment of COVID-19, a big question looms: How much will it cost? The drug's manufacturer, Gilead Sciences, is donating its current stock, enough to treat about 140,000 patients, reports Barron's , but its pricing decision after that...

FDA Permits Emergency Use of Drug for COVID-19 Patients

Remdesivir might help shorten recovery time

(Newser) - US regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster. It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide. President Trump announced the news at the White House alongside Food...

Fauci: Study Has Proven Drug 'Can Block This Virus'

'This will be the standard of care,' he says

(Newser) - Dr. Anthony Fauci says a trial of the drug remdesivir was so promising that people who took a placebo instead should be informed immediately. "This will be the standard of care,” Fauci, director of the National Institute of Allergy and Infectious Diseases, said Wednesday. "When you know...

Market Jumps on New Study of Remdesivir

Maker Gilead's trial found more patients improved when it was given early

(Newser) - Encouraging news on remdesivir as a potential COVID-19 treatment was followed up with discouraging news . Now, a more optimistic report from the drug's maker—and one that drove a more than 400-point jump at market open despite the release of dour GDP news . Gilead on Wednesday revealed the...

Accidental Post Shows Discouraging Results for Drug

Study on remdesivir was briefly posted on WHO website

(Newser) - An early version of a report on the trial results of a drug touted as a COVID-19 treatment threw cold water on those hopes Thursday. A summary of the clinical trial, conducted in China, was accidentally and briefly posted on a World Health Organization website, STAT reports. It showed remdesivir...

Drug Seems to Be Helping 'Severe' Coronavirus Patients

Gilead's remdesivir shows big promise in Chicago, but official results aren't out

(Newser) - You'll likely be hearing a lot about a drug named remdesivir in the coming days. A report from STAT suggests the drug made by Gilead Sciences is showing big promise in treating "severe" coronavirus patients in Chicago. A big caveat: This is not based on the results of...

16 Stories
We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.